BASTIDE LE CONFORT MEDICAL (BLC.PA) Fundamental Analysis & Valuation

EPA:BLC • FR0000035370

Current stock price

23.05 EUR
-0.75 (-3.15%)
Last:

This BLC.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. BLC.PA Profitability Analysis

1.1 Basic Checks

  • In the past year BLC was profitable.
  • In the past year BLC had a positive cash flow from operations.
  • Of the past 5 years BLC 4 years were profitable.
  • Each year in the past 5 years BLC had a positive operating cash flow.
BLC.PA Yearly Net Income VS EBIT VS OCF VS FCFBLC.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M 100M

1.2 Ratios

  • With a Return On Assets value of 0.08%, BLC is not doing good in the industry: 74.07% of the companies in the same industry are doing better.
  • BLC's Return On Equity of 0.74% is on the low side compared to the rest of the industry. BLC is outperformed by 74.07% of its industry peers.
  • BLC's Return On Invested Capital of 6.43% is fine compared to the rest of the industry. BLC outperforms 74.07% of its industry peers.
  • BLC had an Average Return On Invested Capital over the past 3 years of 6.14%. This is in line with the industry average of 5.91%.
  • The last Return On Invested Capital (6.43%) for BLC is above the 3 year average (6.14%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.08%
ROE 0.74%
ROIC 6.43%
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
BLC.PA Yearly ROA, ROE, ROICBLC.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15

1.3 Margins

  • Looking at the Profit Margin, with a value of 0.11%, BLC is doing worse than 74.07% of the companies in the same industry.
  • BLC's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 8.21%, BLC is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
  • BLC's Operating Margin has been stable in the last couple of years.
  • With a decent Gross Margin value of 67.80%, BLC is doing good in the industry, outperforming 74.07% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BLC has grown nicely.
Industry RankSector Rank
OM 8.21%
PM (TTM) 0.11%
GM 67.8%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
BLC.PA Yearly Profit, Operating, Gross MarginsBLC.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BLC.PA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BLC is creating some value.
  • BLC has about the same amout of shares outstanding than it did 1 year ago.
  • The number of shares outstanding for BLC remains at a similar level compared to 5 years ago.
  • BLC has a better debt/assets ratio than last year.
BLC.PA Yearly Shares OutstandingBLC.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
BLC.PA Yearly Total Debt VS Total AssetsBLC.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • BLC has an Altman-Z score of 1.39. This is a bad value and indicates that BLC is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of BLC (1.39) is comparable to the rest of the industry.
  • BLC has a debt to FCF ratio of 12.90. This is a negative value and a sign of low solvency as BLC would need 12.90 years to pay back of all of its debts.
  • BLC has a Debt to FCF ratio of 12.90. This is in the lower half of the industry: BLC underperforms 62.96% of its industry peers.
  • A Debt/Equity ratio of 5.29 is on the high side and indicates that BLC has dependencies on debt financing.
  • With a Debt to Equity ratio value of 5.29, BLC is not doing good in the industry: 85.19% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 5.29
Debt/FCF 12.9
Altman-Z 1.39
ROIC/WACC1.29
WACC4.98%
BLC.PA Yearly LT Debt VS Equity VS FCFBLC.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • BLC has a Current Ratio of 1.38. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.38, BLC is in the better half of the industry, outperforming 74.07% of the companies in the same industry.
  • BLC has a Quick Ratio of 1.18. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of BLC (1.18) is better than 74.07% of its industry peers.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 1.18
BLC.PA Yearly Current Assets VS Current LiabilitesBLC.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. BLC.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 158.33% over the past year.
  • The earnings per share for BLC have been decreasing by -46.37% on average. This is quite bad
  • The Revenue has been growing slightly by 6.35% in the past year.
  • The Revenue has been growing slightly by 5.12% on average over the past years.
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%

3.2 Future

  • Based on estimates for the next years, BLC will show a small growth in Earnings Per Share. The EPS will grow by 5.90% on average per year.
  • BLC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.69% yearly.
EPS Next Y-12.23%
EPS Next 2Y-1.23%
EPS Next 3Y5.9%
EPS Next 5YN/A
Revenue Next Year4.14%
Revenue Next 2Y4.76%
Revenue Next 3Y5.03%
Revenue Next 5Y7.69%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BLC.PA Yearly Revenue VS EstimatesBLC.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
BLC.PA Yearly EPS VS EstimatesBLC.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.5 1 1.5 2 2.5

More info and screens

Find the best growth stocksShow best growing peers

3

4. BLC.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 329.29, which means the current valuation is very expensive for BLC.
  • BLC's Price/Earnings ratio is a bit more expensive when compared to the industry. BLC is more expensive than 74.07% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 25.61, BLC is valued quite expensively.
  • A Price/Forward Earnings ratio of 12.50 indicates a correct valuation of BLC.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BLC indicates a somewhat cheap valuation: BLC is cheaper than 62.96% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.79, BLC is valued a bit cheaper.
Industry RankSector Rank
PE 329.29
Fwd PE 12.5
BLC.PA Price Earnings VS Forward Price EarningsBLC.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BLC indicates a rather cheap valuation: BLC is cheaper than 88.89% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, BLC is valued a bit cheaper than 77.78% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.33
EV/EBITDA 5.56
BLC.PA Per share dataBLC.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.23%
EPS Next 3Y5.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BLC.PA Dividend Analysis

5.1 Amount

  • BLC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BLC.PA Fundamentals: All Metrics, Ratios and Statistics

BASTIDE LE CONFORT MEDICAL

EPA:BLC (3/26/2026, 5:29:59 PM)

23.05

-0.75 (-3.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-18
Earnings (Next)05-14
Inst Owners12.76%
Inst Owner ChangeN/A
Ins Owners1.63%
Ins Owner ChangeN/A
Market Cap169.88M
Revenue(TTM)491.18M
Net Income(TTM)533.00K
Analysts77.14
Price Target36.21 (57.09%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP106.75%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.39%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-8.26%
EPS NY rev (3m)-26.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.26%
Revenue NY rev (3m)0.26%
Valuation
Industry RankSector Rank
PE 329.29
Fwd PE 12.5
P/S 0.35
P/FCF 5.33
P/OCF 1.85
P/B 2.36
P/tB N/A
EV/EBITDA 5.56
EPS(TTM)0.07
EY0.3%
EPS(NY)1.84
Fwd EY8%
FCF(TTM)4.32
FCFY18.76%
OCF(TTM)12.48
OCFY54.13%
SpS66.65
BVpS9.79
TBVpS-16.26
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.93
Profitability
Industry RankSector Rank
ROA 0.08%
ROE 0.74%
ROCE 8.75%
ROIC 6.43%
ROICexc 6.81%
ROICexgc 12.17%
OM 8.21%
PM (TTM) 0.11%
GM 67.8%
FCFM 6.49%
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
ROICexc(3y)6.57%
ROICexc(5y)6.12%
ROICexgc(3y)13.99%
ROICexgc(5y)12.76%
ROCE(3y)8.36%
ROCE(5y)7.81%
ROICexgc growth 3Y3.04%
ROICexgc growth 5Y-0.89%
ROICexc growth 3Y7.75%
ROICexc growth 5Y0.36%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score8
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 5.29
Debt/FCF 12.9
Debt/EBITDA 3.78
Cap/Depr 99.07%
Cap/Sales 12.23%
Interest Coverage 250
Cash Conversion 91.09%
Profit Quality 5980.3%
Current Ratio 1.38
Quick Ratio 1.18
Altman-Z 1.39
F-Score8
WACC4.98%
ROIC/WACC1.29
Cap/Depr(3y)93.32%
Cap/Depr(5y)92.23%
Cap/Sales(3y)11.17%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
EPS Next Y-12.23%
EPS Next 2Y-1.23%
EPS Next 3Y5.9%
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
Revenue Next Year4.14%
Revenue Next 2Y4.76%
Revenue Next 3Y5.03%
Revenue Next 5Y7.69%
EBIT growth 1Y18.78%
EBIT growth 3Y7.18%
EBIT growth 5Y5.9%
EBIT Next Year138.04%
EBIT Next 3Y38.82%
EBIT Next 5YN/A
FCF growth 1Y1.48%
FCF growth 3Y107.15%
FCF growth 5Y33.43%
OCF growth 1Y13.72%
OCF growth 3Y17.38%
OCF growth 5Y14.21%

BASTIDE LE CONFORT MEDICAL / BLC.PA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?

ChartMill assigns a fundamental rating of 4 / 10 to BLC.PA.


Can you provide the valuation status for BASTIDE LE CONFORT MEDICAL?

ChartMill assigns a valuation rating of 3 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Overvalued.


Can you provide the profitability details for BASTIDE LE CONFORT MEDICAL?

BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 5 / 10.


What is the expected EPS growth for BASTIDE LE CONFORT MEDICAL (BLC.PA) stock?

The Earnings per Share (EPS) of BASTIDE LE CONFORT MEDICAL (BLC.PA) is expected to decline by -12.23% in the next year.


Can you provide the dividend sustainability for BLC stock?

The dividend rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 0 / 10 and the dividend payout ratio is 106.75%.